Adherence to osteoporosis drugs and fracture prevention: No evidence of healthy adherer bias in a frail cohort of seniors

Osteoporosis International

Volumn 22, Issue 3, 2011, Pages 943-954

  Cadarette, S M ^a,b,c   Solomon, D H ^b,c   Katz, J N ^b,c   Patrick, A R ^b,c   Brookhart, M A ^b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d University of North Carolina at Chapel Hill   (United States)

Author keywords

Bones; Fractures; Medication adherence; Osteoporosis; Selection bias

Indexed keywords

ALENDRONIC ACID; CALCITONIN; RALOXIFENE; RISEDRONIC ACID;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; FEMALE; FRAIL ELDERLY; HIP FRACTURES; HUMANS; HUMERUS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT COMPLIANCE; PENNSYLVANIA; RADIUS FRACTURES; RALOXIFENE; ULNA FRACTURES;

EID: 79951673238     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1309-z     Document Type: Article

References (32)

1. R Burge B Dawson-Hughes DH Solomon, et al. 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 475 10.1359/jbmr.061113 17144789 (Pubitemid 46797130)
2. C MacLean S Newberry M Maglione, et al. 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 197 213 18087050 (Pubitemid 351665507)
3. P Kothawala E Badamgarav S Ryu, et al. 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 10.4065/82.12.1493 18053457 (Pubitemid 350211697)
4. ES Siris PL Selby KG Saag, et al. 2009 Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3 S13 10.1016/j.amjmed.2008.12.002 19187810
5. MM Wilkes RJ Navickis WW Chan, et al. 2010 Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials Osteoporos Int 21 679 688 1:CAS:528:DC%2BC3cXivVGqtb4%3D 10.1007/s00198-009-0991-1 19572092
6. V Rabenda M Hiligsmann JY Reginster 2009 Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence Expert Opin Pharmacother 10 2303 2315 1:CAS:528:DC%2BD1MXhtFCgtb7E 10.1517/ 14656560903140533 19640210
7. Imaz I, Zegarra P, Gonzalez-Enriquez J et al. (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. doi: 10.1007/s00198-00009-01134-00194
8. BB Granger K Swedberg I Ekman, et al. 2005 Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial Lancet 366 2005 2011 1:CAS:528:DC%2BD2MXht12ku7nP 10.1016/S0140-6736(05)67760-4 16338449 (Pubitemid 41773375)
9. SH Simpson DT Eurich SR Majumdar, et al. 2006 A meta-analysis of the association between adherence to drug therapy and mortality BMJ 333 15 10.1136/bmj.38875.675486.55 16790458
10. J Curtis J Larson E Delzell, et al. 2009 Does the benefit of medication adherence relate more to a drug effect or the behavior itself? Quantifying the effect of adherence behavior using data from the placebo arms of the WHI Arthritis Rheum 60 Suppl 10 613 (abstract)
11. American College of Physicians 2008 Information on cost-effectiveness: an essential product of a national comparative effectiveness program Ann Intern Med 148 956 961
12. JN Rasmussen A Chong DA Alter 2007 Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction Jama 297 177 186 1:CAS:528:DC%2BD2sXksVyisA%3D%3D 10.1001/jama.297.2.177 17213401 (Pubitemid 46089734)
13. Janz NK, Champion VL, Strecher VJ (2002) The health belief model. In: Glanz K, Rimer BK, Lewis FM (eds) Health behavior and health education: theory, research, and practice. Jossey-Bass, San Francisco, pp 45-66
14. MR DiMatteo KB Haskard SL Williams 2007 Health beliefs, disease severity, and patient adherence: a meta-analysis Med Care 45 521 528 10.1097/MLR. 0b013e318032937e 17515779
15. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497 1:CAS:528:DC%2BD2MXntVCisL0%3D 10.1056/NEJMra050100 16079372 (Pubitemid 41127293)
16. JA Cramer A Roy A Burrell, et al. 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359 (Pubitemid 351160875)
17. AM Peterson DP Nau JA Cramer, et al. 2007 A checklist for medication compliance and persistence studies using retrospective databases Value Health 10 3 12 10.1111/j.1524-4733.2006.00139.x 17261111 (Pubitemid 46161090)
18. Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol. doi: 10.1097/BOR. 0b013e32833ac7fe
19. HA Pols D Felsenberg DA Hanley, et al. 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Fosamax International Trial Study Group Osteoporos Int 9 461 468 1:CAS:528:DyaK1MXkt1CktrY%3D 10.1007/PL00004171 10550467 (Pubitemid 29231740)
20. S Suissa 2008 Immeasurable time bias in observational studies of drug effects on mortality Am J Epidemiol 2008 329 335 10.1093/aje/kwn135 (Pubitemid 352019783)
21. WA Ray MR Griffin RL Fought, et al. 1992 Identification of fractures from computerized Medicare files J Clin Epidemiol 45 703 714 1:STN:280: DyaK38zhsl2lug%3D%3D 10.1016/0895-4356(92)90047-Q 1619449
22. SM Cadarette JN Katz MA Brookhart, et al. 2008 Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture Ann Intern Med 148 637 646 18458276 (Pubitemid 351669108)
23. SA Foster KA Foley ES Meadows, et al. 2008 Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates BMC Womens Health 8 24 10.1186/1472-6874-8-24 19105828
24. CS Pickney JA Arnason 2005 Correlation between patient recall of bone densitometry results and subsequent treatment adherence Osteoporos Int 16 1156 1160 10.1007/s00198-004-1818-8 15744452 (Pubitemid 41225103)
25. MA Brookhart AR Patrick J Avorn, et al. 2007 Adherence to lipid-lowering therapy and the use of preventive health care services: an investigation of the healthy user effect Am J Epidemiol 120 251 256
26. CR Dormuth AR Patrick WH Shrank, et al. 2009 Statin adherence and risk of accidents: a cautionary tale Circulation 119 2051 2057 1:CAS:528: DC%2BD1MXksVCrsr4%3D 10.1161/CIRCULATIONAHA.108.824151 19349320
27. L Giangregorio L Dolovich A Cranney, et al. 2009 Osteoporosis risk perceptions among patients who have sustained a fragility fracture Patient Educ Couns 74 213 220 10.1016/j.pec.2008.08.001 18977628
28. Sale JEM, Beaton DE, Sujic R et al. (2010) "If it was osteoporosis, I would have really hurt myself." Ambiguity about osteoporosis and osteoporosis care despite a screening program to educate fragility fracture patients. J Eval Clin Pract 16:590-596
29. MF Holick ES Siris N Binkley, et al. 2005 Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy J Clin Endocrinol Metab 90 3215 3224 1:CAS:528:DC%2BD2MXkvFClsLo%3D 10.1210/jc.2004-2364 15797954 (Pubitemid 41014278)
30. Miller PD, Derman RJ (2010) What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int. doi: 10.1007/s00198-010-1208-3
31. MA Brookhart J Avorn JN Katz, et al. 2007 Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance Am J Med 120 251 256 10.1016/j.amjmed.2006.03.029 17349448 (Pubitemid 46341156)
32. EE Roughead E Ramsay K Priess, et al. 2009 Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates Pharmacoepidemiol Drug Saf 18 69 75 10.1002/pds.1687 19111013